Second, a history of neoadjuvant chemotherapy made pathological evaluation for the presence of lymph node metastasis challenging; therefore, the number of HER2-positive type and triple-negative type breast cancers were limited by neoadjuvant chemotherapy, potentially creating a selection bias. This evidence concerns the gene ERBB2 and breast carcinoma.